Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Dual chemo combo with great results
View:
Post by N0taP00p on Feb 16, 2023 7:18pm

Dual chemo combo with great results

Very interesting study (see limitations in article) with great results from treating BCG resistant NMIBC patients with a combo-chemo treatment. More than 80% of patients showed no recurrence after 2 years. Minor side effects too. Requires monthly treatment though. But still a great alternative to removing a bladder.  

https://www.cancer.gov/news-events/cancer-currents-blog/2022/bladder-cancer-chemo-effective-alternative
Comment by N0taP00p on Feb 16, 2023 7:21pm
If the link doesn't work look for  For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to BCG
Comment by Pandora on Feb 16, 2023 7:40pm
https://www.cancer.gov/news-events/cancer-currents-blog/2022/bladder-cancer-chemo-effective-alternative-bcg
Comment by DJDawg on Feb 16, 2023 8:51pm
6 once a week instillations to make for the induction then monthly instillations....indefinitely. It is an option for sure. Just leaves lots of room for other agents, such as ours. Chemo can be irritating so not sure that they patients were thrilled at the never-ending monthly instillations.
Comment by Gooseybear on Feb 16, 2023 8:59pm
I've been through 20 rounds of BCG. It's not good!
Comment by Gooseybear on Feb 16, 2023 9:01pm
Have to get Urologist and Oncologist on board.
Comment by wildbird1 on Feb 16, 2023 9:11pm
NOtaPOOp maybe you should learn to read... The 82 % in your article is for High-Risk(NMIBC) these are the regular patients that BCG treat, with about the same CR% results. TLT is treating BCG-Resistant (NMIBC) absolutely not the same patients...if TLT was treating the same patients as in your article(High-Risk NMIBC) TLT CR% could easily be over 90-95% CR.
Comment by N0taP00p on Feb 17, 2023 12:03am
Wildbird1 - yes, you're right. Thanks for the correction. I should have caught that.  Sheesh.   Btw, where did you earn your Bachelor's in Public Civility from?  Bencro High? 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250